Bio-Techne (TECH) Projected to Post Earnings on Wednesday

Key Points

• Bio-Techne is expected to release its Q4 2025 earnings before the market opens on August 6th, with analysts predicting earnings of $0.49 per share and revenue of $315.14 million.
• The firm has initiated a share buyback plan that allows for the repurchase of up to $500 million in shares, indicating the board's belief that the stock is undervalued.
• Recent analyst reports have led to a range of target prices, with the average target currently at $69.58, reflecting a consensus rating of "Moderate Buy."

Bio-Techne (NASDAQ:TECH - Get Free Report) is anticipated to post its Q4 2025 quarterly earnings results before the market opens on Wednesday, August 6th. Analysts expect Bio-Techne to post earnings of $0.49 per share and revenue of $315.14 million for the quarter.

Bio-Techne (NASDAQ:TECH - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.51 by $0.05. Bio-Techne had a return on equity of 13.17% and a net margin of 10.89%. The company had revenue of $316.18 million during the quarter, compared to the consensus estimate of $317.92 million. During the same period last year, the company earned $0.48 EPS. Bio-Techne's revenue for the quarter was up 4.2% on a year-over-year basis. On average, analysts expect Bio-Techne to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Bio-Techne Stock Performance

NASDAQ TECH traded down $1.36 during trading hours on Friday, hitting $53.37. The company's stock had a trading volume of 233,658 shares, compared to its average volume of 2,010,872. Bio-Techne has a 12 month low of $46.01 and a 12 month high of $81.30. The company's 50 day simple moving average is $51.75 and its two-hundred day simple moving average is $57.20. The company has a market cap of $8.37 billion, a P/E ratio of 64.91, a price-to-earnings-growth ratio of 2.76 and a beta of 1.39. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.71 and a quick ratio of 2.58.

Bio-Techne announced that its board has approved a stock repurchase program on Wednesday, May 7th that allows the company to repurchase $500.00 million in shares. This repurchase authorization allows the biotechnology company to purchase up to 6.5% of its stock through open market purchases. Stock repurchase programs are often a sign that the company's board believes its shares are undervalued.

Bio-Techne Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 30th. Investors of record on Monday, May 19th were issued a $0.08 dividend. This represents a $0.32 annualized dividend and a yield of 0.6%. The ex-dividend date was Monday, May 19th. Bio-Techne's dividend payout ratio (DPR) is presently 39.02%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Royal Bank Of Canada reduced their price objective on Bio-Techne from $72.00 to $63.00 and set a "sector perform" rating for the company in a report on Thursday, May 8th. TD Cowen began coverage on Bio-Techne in a report on Wednesday, July 9th. They issued a "buy" rating and a $65.00 price objective for the company. KeyCorp restated a "sector weight" rating on shares of Bio-Techne in a research note on Wednesday, April 9th. Wall Street Zen lowered shares of Bio-Techne from a "buy" rating to a "hold" rating in a research report on Sunday, June 8th. Finally, Benchmark reaffirmed a "buy" rating and set a $75.00 price target on shares of Bio-Techne in a research report on Thursday, June 5th. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $69.58.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Bio-Techne stock. Woodline Partners LP lifted its stake in shares of Bio-Techne Corp (NASDAQ:TECH - Free Report) by 40.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 13,356 shares of the biotechnology company's stock after acquiring an additional 3,814 shares during the quarter. Woodline Partners LP's holdings in Bio-Techne were worth $783,000 at the end of the most recent reporting period. 98.95% of the stock is currently owned by institutional investors.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.